Drug Trial Radar · NCT07225634
A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Sep 14, 2026
Primary completion
Mar 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- AFT Pharmaceuticals, Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- HungaroTrial
- First posted
- Nov 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Combogesic® IV is an intravenous medicine (given by vein) containing a combination of two pain relief (analgesic) medicines called ibuprofen and acetaminophen. The goal of this clinical trial is to study the way that the body processes and clears the intravenous infusion of Combogesic® IV and that it is safe to be used in children and adolescents between the ages of 2 and \<17 years. What will the study involve for participants? * Combogesic® IV will be administered every 6 hours as necessary with a maximum of 4 doses within a 24-hour period as an intravenous infusion for about 15 minutes. * Participants will receive Combogesic® IV for a minimum of 12 hours (2 doses) up to a maximum of 5 days (20 doses). Dosing will be dependent on body weight. * If pain is not sufficiently controlled by Combogesic® IV, opioids may be used as supplementary pain relief at the discretion of the study doctor. * Have their blood samples collected before dosing and at specific times after dosing. The amount of study drug in the blood will be measured, and safety assessments (including blood and urine samples) will be done. * Rate the study drug at the end of the treatment. It is expected that Combogesic® IV will be well tolerated in children and adolescents and that the pharmacokinetics findings will be similar as compared with adults.
Conditions
- Acute Pain
Interventions
Combogesic® IV (fixed-dose combination containing acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion)Drug
Acetaminophen 1000 mg and Ibuprofen 300 mg per 100 mL solution for intravenous infusion administered as a 15-minute infusion, every 6 hours, as necessary.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of treatment-emergent adverse events (TEAEs) associated with exposure to Combogesic® IV in pediatric patientsTime frame: From start of exposure to Combogesic® IV up to 7 days after last dose
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Semmelweis University
Budapest, Hungary · Recruiting
Petz Aladar County Teaching Hospital
Győr, Hungary · Recruiting
University of Pecs
Pécs, Hungary · Recruiting
Zala County St. Rafael Hospital
Zalaegerszeg, Hungary · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.